Optimization of chemotherapy for Burkitt lymphoma

HOVON 127/ SAKK 37/16

Coordinating investigator

Prof. Dr. med.
Frank
Stenner
Universitätsspital Basel
+41 61 265 50 74

In this trial, SAKK and the Haemato Oncology Foundation for Adults in the Netherlands (HOVON) are comparing two different chemotherapies for patients with newly diagnosed Burkitt lymphoma. Burkitt lymphoma is a malignant lymphoma that is classified as a high-risk tumour, i.e. it has characteristics indicative of rapid growth and rapid deterioration of the patient’s condition. The aim of this trial is to improve the treatment outcome and tolerability of chemotherapy for this disease.

Patients will be assigned to one of two groups on a random basis (randomized trial). Randomized trials are an internationally recognized method that enables scientific comparison of treatments. One group of patients will be treated with the current therapeutic standard R-CODOX-M/R-IVAC, while the second group will be given a combination of medicinal products using the DA-EPOCH-R protocol. Both are internationally recognized therapies for this disease, yet in an earlier trial DA-EPOCH-R was found to be more effective and associated with a lower mortality rate than treatment with R-CODOX-M/R-IVAC. This international trial seeks to confirm this finding on a larger scale (260 patients).

Patients will participate in the trial for a total period of 16-18 weeks, after which there will be follow-up examinations for a further five years. All the medicinal products used in this trial are authorized in Europe and Switzerland.

All trials